QTTB
Q32 Bio Inc.
NASDAQ · USHealthcareBiotechnology
$15.13+0.53%
Price as of Jul 20, 2026
QTTB ownership
Q32 Bio Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
100/100
Buys (3m)
4
Sells (3m)
0
Net (3m)
$30.0M
Insiders buyingCluster buying
Insider trades by month Buys Sells
Apr
Aug
Aug
Dec
Feb
Jun
Context3-month price +126.3%Institutions mixed (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Manke Isaacdirector | Option | 53,521 | $2.80 |
| Jun 16, 2026 | LAPORTE KATHLEENdirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | Iwicki Mark Tdirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | Manke Isaacdirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | TZIANABOS ARTHURdirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | GRAYZEL DAVID S.director | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | Thistle Marydirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | Lundberg Sven Antedirector | Grant | 9,810 | $12.64 |
| Jun 16, 2026 | Xu Diyongdirector, 10 percent owner: | Grant | 9,810 | $12.64 |
| Jun 1, 2026 | Xu Diyongdirector, 10 percent owner: | Buy | 625,000 | $8.00 |
| Jun 1, 2026 | Xu Diyongdirector, 10 percent owner: | Buy | 1,250,000 | $8.00 |
| Jun 1, 2026 | ORBIMED ADVISORS LLCdirector, 10 percent owner: | Buy | 625,000 | $8.00 |
| Jun 1, 2026 | ORBIMED ADVISORS LLCdirector, 10 percent owner: | Buy | 1,250,000 | $8.00 |
| Mar 20, 2026 | Violette Shelia M.officer: Chief Scientific Officer | Grant | 37,500 | — |
| Mar 20, 2026 | Morrison Jodie Popedirector, officer: CEO | Grant | 132,000 | — |
| Mar 20, 2026 | Kalowski Leeofficer: CFO and President | Grant | 53,250 | — |
| Feb 27, 2026 | Kalowski Leeofficer: CFO and President | Sell | 3,995 | $4.51 |
| Feb 27, 2026 | Morrison Jodie Popedirector, officer: CEO | Sell | 9,896 | $4.51 |
| Feb 27, 2026 | Violette Shelia M.officer: Chief Scientific Officer | Sell | 2,815 | $4.51 |
| Jan 30, 2026 | Lundberg Sven Antedirector | Grant | 20,363 | $3.60 |
| Jan 30, 2026 | GRAYZEL DAVID S.director | Grant | 16,363 | $3.60 |
| Jan 30, 2026 | LAPORTE KATHLEENdirector | Grant | 23,272 | $3.60 |
| Dec 4, 2025 | Morrison Jodie Popedirector, officer: CEO | Sell | 22,506 | $3.46 |
| Dec 4, 2025 | Kalowski Leeofficer: CFO and President | Sell | 9,072 | $3.46 |
| Oct 27, 2025 | TZIANABOS ARTHURdirector | Grant | 53,521 | $2.80 |
| Oct 27, 2025 | Lundberg Sven Antedirector | Grant | 53,521 | $2.80 |
| Oct 27, 2025 | Iwicki Mark Tdirector | Grant | 53,521 | $2.80 |
| Oct 27, 2025 | Manke Isaacdirector | Grant | 53,521 | $2.80 |
| Oct 27, 2025 | Xu Diyongdirector | Grant | 53,521 | $2.80 |
| Oct 27, 2025 | Thistle Marydirector | Grant | 53,521 | $2.80 |
Source: QTTB SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their QTTB positions over the last 6 months (SEC Form 13F).
Increased
22
New positions
18
Reduced
32
Sold out
17
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 2.3M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 2.3M | May 15, 2026 |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | Unchanged | 2.1M | May 14, 2026 |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | Unchanged | 2.1M | Feb 13, 2026 |
| OPALEYE MANAGEMENT INC. | Increased | 1.3M | May 15, 2026 |
| CARLYLE GROUP INC. | Unchanged | 1.1M | May 8, 2026 |
| CARLYLE GROUP INC. | Unchanged | 1.1M | Feb 13, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Reduced | 493K | Feb 17, 2026 |
| VANGUARD GROUP INC | Increased | 321K | Jan 29, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 320K | May 15, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 320K | Feb 17, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Reduced | 315K | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 306K | May 15, 2026 |
| PFIZER INC | Unchanged | 278K | Feb 12, 2026 |
| MACKENZIE FINANCIAL CORP | New Position | 246K | May 13, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.